NCT01799941View on ClinicalTrials.gov

Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)

PHASE4CompletedINTERVENTIONAL
Enrollment

367

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Pseudobulbar Affect (PBA)StrokeDementiaTraumatic Brain Injury (TBI)
Interventions
DRUG

Nuedexta (DM 20 mg/Q 10 mg)

Single Arm, Open-Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)

Trial Locations (1)

32503

Pensacola

Sponsors
All Listed Sponsors
lead

Avanir Pharmaceuticals

INDUSTRY